Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 3
2013 2
2014 6
2015 2
2016 2
2017 3
2018 2
2020 2
2022 1
2023 3
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.
Zhou C, Solomon B, Loong HH, Park K, Pérol M, Arriola E, Novello S, Han B, Zhou J, Ardizzoni A, Mak MP, Santini FC, Elamin YY, Drilon A, Wolf J, Payakachat N, Uh MK, Rajakumar D, Han H, Puri T, Soldatenkova V, Lin AB, Lin BK, Goto K; LIBRETTO-431 Trial Investigators. Zhou C, et al. Among authors: mak mp. N Engl J Med. 2023 Nov 16;389(20):1839-1850. doi: 10.1056/NEJMoa2309457. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870973 Free PMC article. Clinical Trial.
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study.
Lee SM, Schulz C, Prabhash K, Kowalski D, Szczesna A, Han B, Rittmeyer A, Talbot T, Vicente D, Califano R, Cortinovis D, Le AT, Huang D, Liu G, Cappuzzo F, Reyes Contreras J, Reck M, Palmero R, Mak MP, Hu Y, Morris S, Höglander E, Connors M, Biggane AM, Vollan HK, Peters S. Lee SM, et al. Among authors: mak mp. Lancet. 2023 Aug 5;402(10400):451-463. doi: 10.1016/S0140-6736(23)00774-2. Epub 2023 Jul 6. Lancet. 2023. PMID: 37423228 Clinical Trial.
A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.
Mak MP, Tong P, Diao L, Cardnell RJ, Gibbons DL, William WN, Skoulidis F, Parra ER, Rodriguez-Canales J, Wistuba II, Heymach JV, Weinstein JN, Coombes KR, Wang J, Byers LA. Mak MP, et al. Clin Cancer Res. 2016 Feb 1;22(3):609-20. doi: 10.1158/1078-0432.CCR-15-0876. Epub 2015 Sep 29. Clin Cancer Res. 2016. PMID: 26420858 Free PMC article.
Latin American Consensus on the Treatment of Head and Neck Cancer.
Matos LL, Kowalski LP, Chaves ALF, de Oliveira TB, Marta GN, Curado MP, de Castro Junior G, Farias TP, Bardales GS, Cabrera MA, Capuzzo RC, de Carvalho GB, Cernea CR, Dedivitis RA, Dias FL, Estefan AM, Falco AH, Ferraris GA, Gonzalez-Motta A, Gouveia AG, Jacinto AA, Kulcsar MAV, Leite AK, Lira RB, Mak MP, De Marchi P, de Mello ES, de Matos FCM, Montero PH, de Moraes ED, de Moraes FY, Morais DCR, Poenitz FM, Poitevin A, Riveros HO, Sanabria Á, Ticona-Castro M, Vartanian JG, Viani G, Vines EF, William Junior WN, Conway D, Virani S, Brennan P; HEADSpAcE Consortium. Matos LL, et al. Among authors: mak mp. JCO Glob Oncol. 2024 Apr;10:e2300343. doi: 10.1200/GO.23.00343. JCO Glob Oncol. 2024. PMID: 38603656 Review.
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.
Machiels JP, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, Alves G, Lima IPF, Hughes BGM, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnał M, Delord JP, Mesía R, Taberna M, Waldron JN, Simon C, Grégoire V, Harrington KJ, Swaby RF, Zhang Y, Gumuscu B, Bidadi B, Siu LL; KEYNOTE-412 Investigators. Machiels JP, et al. Lancet Oncol. 2024 May;25(5):572-587. doi: 10.1016/S1470-2045(24)00100-1. Epub 2024 Mar 29. Lancet Oncol. 2024. PMID: 38561010 Clinical Trial.
Managing oncology clinical trials during COVID-19 pandemic.
Arai RJ, Moniz CMV, Chen ATC, Mak MP, Chammas R, Hoff PM. Arai RJ, et al. Among authors: mak mp. Contemp Clin Trials Commun. 2020 Sep;19:100637. doi: 10.1016/j.conctc.2020.100637. Epub 2020 Aug 13. Contemp Clin Trials Commun. 2020. PMID: 32835128 Free PMC article.
Patient's perceptions of oral and oropharyngeal cancer diagnosis disclosure: communication aspects based on SPIKES protocol.
Alves CGB, Ribeiro ACP, Brandão TB, Tonaki JO, Pedroso CM, Rivera C, Epstein JB, Migliorati CA, Kowalski LP, Mak MP, Castro G, Lopes MA, Santos-Silva AR. Alves CGB, et al. Among authors: mak mp. Oral Surg Oral Med Oral Pathol Oral Radiol. 2023 Apr;135(4):518-529. doi: 10.1016/j.oooo.2022.12.008. Epub 2022 Dec 23. Oral Surg Oral Med Oral Pathol Oral Radiol. 2023. PMID: 36740563
Palliative chemotherapy outcomes in patients with ECOG-PS higher than 1.
Caires-Lima R, Cayres K, Protásio B, Caires I, Andrade J, Rocha L, Takahashi TK, Hoff PM, de Castro G Jr, Mak MP. Caires-Lima R, et al. Among authors: mak mp. Ecancermedicalscience. 2018 Apr 30;12:831. doi: 10.3332/ecancer.2018.831. eCollection 2018. Ecancermedicalscience. 2018. PMID: 29743951 Free PMC article.
25 results